Testosterone therapy considerations in oestrogen, progesterone and androgen receptor-positive breast cancer in a transgender man

Clin Endocrinol (Oxf). 2020 Sep;93(3):355-357. doi: 10.1111/cen.14263. Epub 2020 Jun 26.

Authors

Melanie Light¹, Thomas McFarlane², Andrew Ives³, Bhaumik Shah⁴, Elgene Lim^{5

6}, Mathis Grossmann^{1

2}, Jeffrey D Zajac^{1

2}, Ada S Cheung^{1

2}

Affiliations

¹ Endocrinology Department, Austin Health, Heidelberg, Vic., Australia.
² Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Vic., Australia.
³ Masada Private Hospital, St Kilda East, Vic., Australia.
⁴ Aurora Specialists Care, Fitzroy, Vic., Australia.
⁵ Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
⁶ St Vincent's Clinical School, University of New South Wales, Darlinghurst, NSW, Australia.

PMID: 32521051
DOI: 10.1111/cen.14263

No abstract available

Keywords: breast cancer; testosterone; transgender.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Breast Neoplasms* / drug therapy
Estrogens
Humans
Male
Progesterone
Receptors, Androgen / genetics
Testosterone
Transgender Persons*

Substances

Estrogens
Receptors, Androgen
Testosterone
Progesterone